webinar register page

Webinar banner
Genetics, the PROMISE Study, and Their Roles in Prostate Cancer: A Town hall
Prostate cancer is a very common diagnosis in men. Genetics can help men with prostate cancer find out if they have genetic factors that may influence their disease and treatment options. This webinar will present you with information on new treatments and help you understand your family risk through genetics.

Join Rob Finch, Director of Urology Medical Affairs at Myriad Genetics, and Dr. Channing Paller, associate professor of Oncology and Urology at Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, as they discuss genetics in prostate cancer and the PROMISE study, a new research study led by physicians from Johns Hopkins University and University of Washington.

Jul 20, 2022 06:00 PM in Eastern Time (US and Canada)

Webinar logo
* Required information
Loading
Myriad and the PROMISE study are not affiliated.

Speakers

Rob Finch
Director of Urology Medical Affairs @Myriad Genetics
Rob Finch is a Certified Genetic Counselor. He graduated with a Masters Degree in Human Genetics from the University of Pittsburgh in May 2001. Rob worked at Memorial Sloan-Kettering Cancer Center from May 2001 to September 2003, where he led the Hereditary Colorectal Cancer Registry, as well as provided risk assessment and genetic testing to patients through the Clinical Genetics Service. In September 2003, Rob joined the Myriad Genetics Team, where he has served as a Regional Medical Specialist and Institutional Account Executive for the Oncology Division and currently serves as a Director of Urology Medical Affairs. Rob works to educate and provide clinical support to healthcare providers who treat prostate cancer for Myriad’s BRACAnalysis CDx®, MyRisk™ Hereditary Cancer Test, and Prolaris®.
Dr. Channing Paller
Associate Professor of Oncology & Urology @Johns Hopkins
Dr. Paller is associate professor of Oncology and Urology at Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, and associate director for Oncology of the Johns Hopkins Clinical Research Network. She is a clinician scientist focused on translating basic scientific findings into treatments that will improve clinical outcomes and reduce toxicities for men with prostate cancer. Dr. Paller is a lead investigator of the PROMISE registry and, as an expert in clinical trial design, she leads multiple clinical trials of innovative new treatments and treatment combinations employing germline and somatic biomarkers. She earned her M.D. at Harvard Medical School and completed her medical residency and fellowship in Medical Oncology at Johns Hopkins.